Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive…
The latest Global Hepatitis Report by the World Health Organization (WHO) for 2024 reveals a concerning rise in deaths attributed to viral hepatitis. This disease now stands as the second…
In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00…
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at…
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica®…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company specializing in genetic diseases and cancers, unveiled findings from the exploratory CMR imaging substudy of its Phase 3 trial, ATTRibute-CM, evaluating…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome…
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the…
Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive…
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients…